The therapeutic community is abuzz with anticipation surrounding retatrutide, a new dual GIP and GLP-1 receptor that’s exhibiting significant promise in clinical trials for managing obesity. Unlike some existing weight loss approaches, retatrutide appears to provide a greater substantial reduction in body size and improve metabolic markers, parti